Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Qian-Jun Chen"'
Autor:
Yu-Zhu Zhang, Jia-Yao Yang, Rui-Xian Wu, Chen Fang, Hai Lu, Hua-Chao Li, Dong-Mei Li, Hua-Li Zuo, Li-Ping Ren, Xiao-Yuan Liu, Rui Xu, Jia-Huai Wen, Hsien-Da Huang, Ri Hong, Qian-Jun Chen
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Xihuang pill, an approved Chinese medicine formula (state medical permit number. Z11020073), is a commonly used adjuvant drug for cancer patients in China. Xihuang pill has a satisfactory effect in treating breast cancer in clinics, especially triple
Externí odkaz:
https://doaj.org/article/a35474bf6ee54fdbb52e02c246097f74
Autor:
Hong-Fei Gao, Zhiyong Wu, Ying Lin, Xiang-Yang Song, Yin Cao, Qian-Jun Chen, Gangling Zhang, Peifen Fu, Zhenzhen Liu, Liu-Lu Zhang, Ci-Qiu Yang, Mei Yang, Teng Zhu, Fei Ji, Jie-Qing Li, Min-Yi Cheng, Kun Wang
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Although dual blockade HER2-based neoadjuvant chemotherapy is associated with excellent outcomes for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, pertuzumab is not available to all patients due to cost. The opti
Externí odkaz:
https://doaj.org/article/d036c3fd9787471f81ac0cd6a23b620a
Autor:
Zheng-Meng Hou, Ying Xiong, Jia-Shun Luo, Yan-Li Fang, Muhammad Haris, Qian-Jun Chen, Ye Yue, Lin Wu, Qi-Chen Wang, Liang-Chao Huang, Yi-Lin Guo, Ya-Chen Xie
Publikováno v:
Petroleum Science. 20:893-909
Autor:
Ying Chen, Wen-Xia Li, Jia-Hua Wu, Geng-Hang Chen, Chun-min Yang, Hai Lu, Xi Wang, Shu-Sen Wang, Heng Huang, Li Cai, Li Zhao, Rou-Jun Peng, Ying Lin, Jun Tang, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, An-Qin Zhang, Fei Xu, Xi-Wen Bi, Jia-Jia Huang, Ji-Bin Li, Dan-Mei Pang, Cong Xue, Yan-Xia Shi, Zhen-Yu He, Huan-Xin Lin, Xin An, Wen Xia, Ye Cao, Ying Guo, Ruo-Xi Hong, Kui-Kui Jiang, Yong-Yi Zhong, Zhong-Yu Yuan, Qian-Jun Chen
Aims: The addition of extended capecitabine after standard neo/adjuvant chemotherapy shows controversial results in triple-negative breast cancer (TNBC) patients between SYSUCC-001 trial and CIBOMA trial. Patients presents different responses to dive
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ba203628270aa39a470217abf416c999
https://doi.org/10.21203/rs.3.rs-1961186/v1
https://doi.org/10.21203/rs.3.rs-1961186/v1
Autor:
Yuan-Qi Zhang, Heng Huang, Anqin Zhang, Ying Lin, Yuhua Song, Zhen Shan, Hongmin Ma, Jianwen Li, Li Cai, Rui Zhuo, Zhiyong Wu, Xiangyang Song, Zhongyu Yuan, Lehong Zhang, Li Zhao, Nan Shao, Ailing Zhang, Jincai Zhong, Herui Yao, Weixiong Yang, Qian-Jun Chen, Kun Wang, Feihai Ling, Hui Liu
Publikováno v:
Cancer Research. 80:OT1-04
In SOFT study, subgroup analysis for hormone receptor-positive (HR+) breast cancer women younger than 35 years indicated better 5-year DFS in OFS+exemestane arm than OFS+tamoxifen. Since only about 11% of women included were younger than 35 years of
Purpose To construct and validate a nomogram and risk stratification model for predicting overall survival (OS) of patients with breast cancer bone metastasis (BCBM).Methods We collected data on BCBM patients between 2010 and 2015 from the Surveillan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2bc19558271b18a9b3db0b60a1f7cd14
https://doi.org/10.21203/rs.3.rs-466150/v1
https://doi.org/10.21203/rs.3.rs-466150/v1
Autor:
Yuanjia Hu, Hsiao Chin Hong, Hua-Li Zuo, Xu Wang, Xiangjun Kong, Hsi-Yuan Huang, Yu-zhu Zhang, Yang-Chi-Dung Lin, Qian-jun Chen, Jing Li, Hsien Da Huang, Yun Tang, Si-yao Hu
Publikováno v:
Acta Pharmacologica Sinica
The purpose of this perspective is to provide insights into the current challenges and opportunities of applying network pharmacology (NP) to illustrate the effectiveness of traditional Chinese medicines (TCMs) against the coronavirus disease 2019 (C
Background:Breast cancer is the most common malignant tumor and the leading cause of death in women. Chemotherapy is one of the most important treatments for breast cancer. However, the development of chemotherapy resistance is the main cause of 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::736fea042515b3a0e5b4aae1096a39cf
https://doi.org/10.21203/rs.3.rs-35979/v1
https://doi.org/10.21203/rs.3.rs-35979/v1
Autor:
Heng Huang, Xin An, Kuikui Jiang, Zhongyu Yuan, Fei Xu, Wen Xia, Shusen Wang, Yanxia Shi, Lehong Zhang, Xi Wang, Xin Hua, Cong Xue, Li Cai, Qian-Jun Chen, Jun Tang, Ruoxi Hong, Wang-Zhong Li, Xiwen Bi, Jia Jia Huang, Ying Lin
Publikováno v:
Journal of Clinical Oncology. 39:521-521
521 Background: Recent clinical trials and meta-analysis have suggested the benefit of adding capecitabine to standard chemotherapy in early-stage triple negative breast cancer (TNBC). We aimed to develop an individualized prediction model to quantif
Autor:
Jie-shu You, Li Guo, Mei Huang, Xin-lei Shi, Man-di Lin, Zhen Guo, Ya-li Cao, You-zhi Sun, Qian Xu, Wei-ling Qu, Huan-lan Liu, Yi Lin, Qian-Jun Chen, Jianping Chen
Background: Hair loss is the one of the most common side effects of chemotherapy, which can cause persistent negative emotions, further affecting therapeutic effects and reducing the quality of life. However, there is no clinically safe and effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3cd0b1badd53e108031d5fec230654f
https://doi.org/10.21203/rs.2.222/v1
https://doi.org/10.21203/rs.2.222/v1